Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Brian Nagle

Neurology Madison, WI Medical Doctor

NPI 1346745890 CMS profile 7228482

20 S Park St Ste 202, Madison, WI 53715

Open in the dashboard

General payments

$25,173

134 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brian Nagle of Madison, WI is reported in the CMS Open Payments database as having received $25,173 across 134 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $99 1
2024 General $259 2
2023 General $2,097 61
2022 General $22,432 61
2021 General $105 5
2020 General $133 1
2019 General $48 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brian Nagle
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Brian Nagle were reported at $99. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Brian Nagle Neurology median Middle half National median
2019 $48 $474 $118–$2,177 $163
2020 $133 $367 $82–$2,309 $114
2021 $105 $438 $104–$2,547 $132
2022 $22,432 $442 $103–$2,388 $149
2023 $2,097 $464 $119–$2,312 $160
2024 $259 $468 $119–$2,323 $164
2025 $99 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $20,995 15 payments
  2. Amneal Pharmaceuticals LLC $954 17 payments
  3. AbbVie, Inc. $746 26 payments
  4. ACADIA Pharmaceuticals Inc $721 20 payments
  5. Amgen Inc. $259 2 payments
  6. Teva Pharmaceuticals USA, Inc. $195 8 payments
  7. Merz Pharmaceuticals, LLC $187 7 payments
  8. Abbott Laboratories $172 5 payments
  9. Merz North America, Inc. $133 1 payment
  10. US WorldMeds, LLC $125 6 payments
  11. Other $686 27 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Grant $20,000 1 payment
  2. Food and Beverage $3,614 115 payments
  3. Travel and Lodging $722 11 payments
  4. Consulting Fee $642 1 payment
  5. Education $195 6 payments
Products named General payments · program years 2019–2025
  1. ACTIVA PC $20,000 1 payment
  2. PERCEPT PC BRAINSENSE $995 14 payments
  3. NUPLAZID $677 18 payments
  4. BOTOX $491 13 payments
  5. Xeomin $299 7 payments
  6. RYTARY $296 15 payments
  7. UPLIZNA $259 2 payments
  8. INFINITY $172 5 payments
  9. AUSTEDO $167 7 payments
  10. DUOPA $155 7 payments
  11. Other $951 43 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

628

Median for Neurology: 833

Drug cost

$151,883

Median for Neurology: $202,670

Branded share of claims

67.4%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 11 $87,321
Rytary Carbidopa/Levodopa Brand 39 $41,178
Carbidopa-Levodopa Carbidopa/Levodopa Brand 327 $8,157
Rivastigmine Generic 28 $4,566
Rasagiline Mesylate Generic 23 $4,284
Tetrabenazine Generic 16 $1,674
Gabapentin Generic 31 $1,211
Levetiracetam Generic 21 $1,178
Propranolol Hcl Er Propranolol Hcl Brand 12 $723
Topiramate Generic 20 $453

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$39,565

Medicare's payments for the services billed

Medicare patients

195

Average age 72

Services billed

790

110 women, 85 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 46%
Depression 33%
Diabetes 29%
Atrial fibrillation 26%
Ischemic heart disease 25%
Chronic kidney disease 20%
Heart failure 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

134 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Wisconsin

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record